Placebo-controlled evaluation of Ritalin side effects

Area of Science:

• Pediatric Neurology
• Psychopharmacology
• Clinical Trials

Background:

• Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
• Stimulant medications, such as Ritalin (methylphenidate), are frequently prescribed for ADHD management.
• Understanding the side effect profile of Ritalin is crucial for optimizing treatment outcomes.

Purpose of the Study:

• To evaluate the frequency of side effects associated with Ritalin therapy in children diagnosed with ADHD.
• To assess the clinical utility of the Barkeley Side Effects Questionnaire (BSEQ) in monitoring these side effects.

Main Methods:

• A randomized, double-blind, placebo-controlled, cross-over trial was conducted in a rural tertiary care clinic.
• 206 children aged 5-15 with ADHD received Ritalin at 0.3 mg/kg or 0.5 mg/kg per dose, or placebo, over separate 2-week periods.
• Parents completed the BSEQ at baseline and weekly to assess side effects.

Main Results:

• Ritalin therapy significantly increased the frequency of insomnia (OR=3.13), appetite disturbance (OR=19.00), stomachache (OR=7.00), headache (OR=5.29), and dizziness (OR=7.50).
• Conversely, Ritalin significantly decreased staring/daydreaming (OR=0.47), irritability (OR=0.33), anxiety (OR=0.42), and nailbiting (OR=0.19).
• The BSEQ demonstrated clinical effectiveness in identifying these Ritalin-induced side effects.

Conclusions:

• The Barkeley Side Effects Questionnaire (BSEQ) is a valuable tool for monitoring Ritalin side effects in children with ADHD.
• Routine use of the BSEQ should be considered for patients prescribed stimulant medications for ADHD.
• This systematic monitoring can aid in managing treatment-related adverse events.